Skip to main content
Lonza Group AG logo

Lonza Group AG — Investor Relations & Filings

Ticker · LONN ISIN · CH1255014495 LEI · 549300EFW4H2TCZ71055 SW Manufacturing
Open in API
Filings indexed 137 across all filing types
Latest filing 2024-11-12 Regulatory Filings
Country CH Switzerland
Listing SW LONN

About Lonza Group AG

https://www.lonza.com/

Lonza Group AG is a global contract development and manufacturing organization (CDMO) that partners with the pharmaceutical, biotech, and nutrition industries. The company provides integrated services that span the entire product lifecycle, from early-phase research and process development to custom, large-scale commercial manufacturing. Its expertise covers a wide range of therapeutic modalities, including mammalian and microbial biopharmaceuticals, small molecules, cell and gene therapies, highly potent active pharmaceutical ingredients (APIs), peptides, and bioconjugates. By combining advanced scientific and technological insights with world-class manufacturing and regulatory expertise, Lonza supports its customers in developing and commercializing innovative medicines and health products for patients worldwide.

Recent filings

Filing Released Lang Actions
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites
Regulatory Filings Classification · 100% confidence The document is a press release dated 12.11.2024, announcing a specific business investment: Lonza expanding its bioconjugation capabilities in Visp. It details capacity expansion, job creation, expected operational dates, and includes quotes from management and financial highlights for H1 2024. This content is characteristic of an announcement regarding business operations, strategy, or significant capital expenditure, but it is not a formal regulatory filing like a 10-K, an earnings release (ER) which focuses purely on period results, or a formal capital/financing update (CAP) which usually details debt/equity issuance. Since it is a general corporate announcement about expansion and investment, and does not fit the specific definitions for M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), it most closely aligns with a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the best fit as a general announcement category for non-standard, yet material, corporate news that doesn't fit the other specific codes, although it could also be argued as a type of Capital/Financing Update (CAP) due to the investment, but it lacks the typical structure of a financing announcement. However, based on the content being a news release about operational expansion, RNS serves as the most appropriate general corporate news category among the choices provided, as it is not a formal report itself (ruling out RPA).
2024-11-12 English
Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024
Earnings Release Classification · 100% confidence The document is titled 'Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024' and is released as an 'Ad hoc announcement pursuant to Art. 53 LR'. It provides a qualitative summary of the third-quarter performance, confirms the full-year outlook, and discusses operational highlights (like acquisitions and facility updates). This content structure—a brief update on recent performance without full, detailed financial statements—is characteristic of an Earnings Release (ER), which typically precedes or is the initial announcement of period results. Although it is qualitative, it serves the function of an earnings announcement for the period. It is not a comprehensive Interim Report (IR) or Annual Report (10-K), nor is it a transcript (CT) or a presentation (IP). Given the focus on confirming the outlook based on Q3 performance, ER is the most appropriate classification. Q3 2024
2024-10-24 English
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
M&A Activity Classification · 99% confidence The document is a press release from Lonza Group AG dated 22.10.2024, announcing the extension of a collaboration for commercial supply of Antibody-Drug Conjugates (ADCs). It details operational expansions, new capacity construction, and future service agreements. This type of announcement, focusing on strategic business developments, partnerships, and operational updates rather than mandatory financial disclosures (like 10-K, IR, or ER), typically falls under general corporate news or regulatory announcements. Since it is a formal announcement of a significant business event (partnership extension and capacity expansion) and not a specific financial report, dividend notice, or management change, it best fits the general 'Regulatory Filings' (RNS) category as a broad corporate disclosure, or potentially a 'Capital/Financing Update' (CAP) if the expansion was framed as a major investment, but RNS is the most appropriate general category for non-standard press releases.
2024-10-22 English
Lonza Nominates David Meline as Independent Board Member
Board/Management Information Classification · 100% confidence The document is a press release dated October 3, 2024, announcing the nomination of David Meline as an Independent Member of the Board of Directors and noting that Olivier Verscheure will not stand for re-election at the 2025 Annual General Meeting (AGM). This content directly relates to changes in the company's board composition and governance structure. This fits the definition of 'Board/Management Information' (MANG). While it mentions the AGM, the primary focus is the personnel change, not the meeting materials (AGM-R) or voting results (DVA). It is not a formal regulatory filing like a 10-K or an earnings release (ER).
2024-10-03 English
Lonza Nominates David Meline as Independent Board Member
Board/Management Information Classification · 100% confidence The document is a press release dated October 3, 2024, announcing the nomination of David Meline as an Independent Member of the Board of Directors, to be proposed at the 2025 Annual General Meeting (AGM). It also mentions that another director will not stand for re-election at the AGM. This content directly relates to changes in the company's board composition and governance structure. This fits the definition of 'Board/Management Information' (MANG). While it mentions the AGM, the primary focus is the personnel change announcement, not the AGM materials themselves (AGM-R) or the voting results (DVA).
2024-10-03 English
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
M&A Activity Classification · 99% confidence The document is a press release dated October 1, 2024, announcing the completion of an acquisition by Lonza Group AG from Roche. It details the strategic rationale, financial terms (USD 1.2 billion), and operational impact of acquiring a large-scale biologics site. This type of announcement, concerning corporate transactions like mergers or acquisitions, directly aligns with the definition of M&A Activity (TAR). It is not a standard periodic financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific corporate action announcement, TAR is the most appropriate classification over the general 'Regulatory Filings' (RNS). The document length is substantial (7163 chars), indicating it is the primary announcement, not just a brief notice of publication (RPA).
2024-10-01 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.